Segment Reporting (Tables)

9 Months Ended

Jul. 31, 2026

The following table summarizes significant segment expenses, other segment items and the measure of segment net loss of the Company's reportable segment for the three and nine months ended July 31, 2026 and 2025:


	Three Months Ended July 31,						Nine Months Ended July 31,
	2026			2025			2026			2025
Research and development expenses:
Chemistry, Manufacturing and Controls(1)	$	4,814		$	11,278		$	22,968		$	30,657
Clinical operations(2)		4,261			4,837			13,426			12,951
Other research and development expenses(3)		2,026			1,139			5,426			4,792
Personnel-related expenses, excluding stock-based compensation		6,877			4,467			17,977			11,991
Stock based compensation		2,112			854			4,743			2,367
Total research and development expenses		20,090			22,575			64,540			62,758
General and administrative expenses:
Personnel-related expenses, excluding stock-based compensation		5,135			2,772			11,642			7,859
Stock based compensation		5,698			1,727			10,015			4,673
Other general and administrative expenses(4)		3,091			2,873			10,970			8,394
Total general and administrative expenses		13,924			7,372			32,627			20,926
Other segment items(5)		(1,513	)		(956	)		(4,687	)		(4,262	)
Net loss	$	32,501		$	28,991		$	92,480		$	79,422

(1) External expenses associated with clinical manufacturing of the Company's lead compound, detalimogene.

(2) External and internal expenses associated with clinical operations related to research and development of the Company's lead compound, detalimogene.

(3) Represents research and development expenses associated with preclinical, medical affairs, regulatory, quality, program management and facility related costs.

(4) Represents general and administrative costs associated with external legal fees, facilities, professional fees, and other overhead costs.

(5) Other segment items include interest income, interest expense, loss on extinguishment of debt and other expenses. A breakdown of each category by period can be seen within the Condensed Statements of Operations and Comprehensive Loss.